These data are in accordance with a recent study in which HCQ-mediated inhibition of lysosome function sensitized a KRASG12D/LKB1Null-driven GEM model of lung cancer to MEK1/2 inhibition (Bhatt et al., 2023). This evidence concerns the gene MAP2K1 and lung cancer.